Key result
New oral anticoagulants (dabigatran, rivaroxaban, and apixaban) require specific management strategies regarding dosing, drug interactions, switching, and perioperative care compared to warfarin.
This practice tool provides practical prescribing information for new oral anticoagulants, including drug interactions, switching protocols, and perioperative management.
PharmacodynamicIncreased risk of bleeding ASA
No takes yet. Share an insight, caveat, or question.
Anne Massicotte (2013) conducted a review in Anticoagulation therapy. New oral anticoagulants (dabigatran, rivaroxaban, apixaban) vs. Warfarin was evaluated. New oral anticoagulants (dabigatran, rivaroxaban, and apixaban) require specific management strategies regarding dosing, drug interactions, switching, and perioperative care compared to warfarin.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: